Plain-English translation of NCT06596915 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage clinical trial testing a new experimental medication called for patients with advanced solid cancers. Researchers want to understand how safe the medication is, how well it is tolerated by patients, and whether it can help fight cancer. This is the first time the medication is being tested in humans.
Standard cancer treatments don't work for everyone, and some patients become unable to tolerate them or have no good treatment options left. This trial explores whether this new medication could offer hope for patients with advanced cancers who have limited choices.
You likely qualify if…
You likely don't qualify if…
You would take as directed by the study team, likely at regular clinic visits where doctors monitor how your body responds and check for side effects. The trial has two parts: first, researchers carefully increase the dose in small groups of patients to find the safest dose, then expand to larger groups to further test safety and whether the treatment helps fight cancer. You would have blood tests, imaging scans, and possibly tissue biopsies to track how you are doing.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Shandong Boan Biotechnology Co., Ltd
Enrollment target
~167 participants
Started
September 2024
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in June 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
primary investigator
Shandong Boan Biotechnology Co., Ltd
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.